Main Article Content
Objective: To investigate the characteristics of patients using fibrinolytics medicine - Alteplase in the treatment of acute ischemic stroke.
Subjects and methods: A retrospective cross-sectional and non-interventional study on 52 stroke patients using Alteplase at Can Tho City General Hospital from April 2019 to October 2020.
Results: Male accounted for 53.8%, average age 58.31 years old. Risk factors included a history of hypertension (53.8%), diabetes (21.8%), stroke (6.4%), atrial fibrillation (2.6%), and smoking.
(15.4%). Common clinical symptoms included weakness/hemiplegia (88.5%), speech disorder (84.6%), facial paralysis (82.7%), and sensory disturbances (71.2%) and oculomotor limitation (23.1%). Complications of extracranial hemorrhage (17%), progressive ischemic stroke (9.7%), allergies (4.8%), new embolism (2.4%) and no cerebral hemorrhage patient. The average NIHSS score at admission was 11.8 ± 7.1 points, decreasing at the time of 24 hours and discharge, respectively, 5.8 ± 5.3 and 4.2 ± 5, 5 points. The difference was statistically significant between the study times.
Conclusion: The average age of patients was 58.31 years old, mainly men. Hypertension, diabetes, and smoking were the most common risk factors. Weakness/hemiplegia, speech disorder, facial
paralysis, and sensory disturbances were common symptoms. The NIHSS score decreased gradually at 24 hours after admission and at discharge compared with the time of admission.
Acute ischemic stroke, Alteplase.